New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes
- 1 April 2012
- journal article
- review article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 59 (16), 1413-1425
- https://doi.org/10.1016/j.jacc.2012.02.008
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- Boehringer-Ingelheim
- AstraZeneca
- Bayer
- Pfizer
- Boehringer Ingelheim
- Bristol-Myers Squibb
- AstraZeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb
- GlaxoSmithKline
- Merck
- Pfizer
- Schering-Plough
- AstraZeneca
- Boehringer Ingelheim
- Bayer
- Boehringer Ingelheim
- Eli Lilly
- Roche
This publication has 35 references indexed in Scilit:
- Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) TrialCell Metabolism, 2012
- Rivaroxaban in Patients with a Recent Acute Coronary SyndromeNew England Journal of Medicine, 2012
- 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary InterventionJournal of the American College of Cardiology, 2011
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndromeEuropean Heart Journal, 2011
- ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)European Heart Journal, 2011
- Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndromeAmerican Heart Journal, 2011
- Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trialEuropean Heart Journal, 2011
- Newly Identified Events in the RE-LY TrialNew England Journal of Medicine, 2010
- Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)BMJ, 2006